Genmab and partner Johnson & Johnson have been boosted by positive mid-stage data on daratumumab for multiple myeloma.
Preliminary results from a 124-patient Phase II study of daratumumab in double refractory MM conducted by J&J’s Janssen Biotech unit, show that the overall response rate was 29.2% in the 16 mg/kg dosing group and the median duration of response was 7.4 months. The trial evaluated MM patients who have received at least three different lines of therapy including both a proteasome inhibitor and an immunomodulatory agent.
Daratumumab showed a manageable safety profile and the full data set will be discussed at an upcoming meeting. The human CD38 monoclonal antibody was granted breakthrough therapy designation from the US Food and Drug Administration in May 2013.
